Susan M. Begelman, MD

Susan M. Begelman, MD
Nuvelo, Inc., San Carlos, CA

Michael R. Jaff, DO
Harvard Medical School and Massachusetts General Hospital, Boston, MA

Correspondence: Susan M. Begelman, MD, FACC, Associate Director, Clinical Sciences/Cardiovascular, Nuvelo, Inc., 201 Industrial Road, Suite 310, San Carlos, CA 94070–6211; [email protected]

Dr. Begelman reported that she has no financial relationships that pose a potential conflict of interest with this article.

Dr. Jaff reported that he has received honoraria for teaching and speaking from the Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership.

At the time this article was written, Dr. Begelman was employed in the Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH.

Susan M. Begelman, MD
Nuvelo, Inc., San Carlos, CA

Michael R. Jaff, DO
Harvard Medical School and Massachusetts General Hospital, Boston, MA

Correspondence: Susan M. Begelman, MD, FACC, Associate Director, Clinical Sciences/Cardiovascular, Nuvelo, Inc., 201 Industrial Road, Suite 310, San Carlos, CA 94070–6211; [email protected]

Dr. Begelman reported that she has no financial relationships that pose a potential conflict of interest with this article.

Dr. Jaff reported that he has received honoraria for teaching and speaking from the Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership.

At the time this article was written, Dr. Begelman was employed in the Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH.

Susan M. Begelman, MD
Nuvelo, Inc., San Carlos, CA

Michael R. Jaff, DO
Harvard Medical School and Massachusetts General Hospital, Boston, MA

Correspondence: Susan M. Begelman, MD, FACC, Associate Director, Clinical Sciences/Cardiovascular, Nuvelo, Inc., 201 Industrial Road, Suite 310, San Carlos, CA 94070–6211; [email protected]

Dr. Begelman reported that she has no financial relationships that pose a potential conflict of interest with this article.

Dr. Jaff reported that he has received honoraria for teaching and speaking from the Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership.

At the time this article was written, Dr. Begelman was employed in the Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH.

John R. Bartholomew, MD
Section of Vascular Medicine, Department of Cardiovascular Medicine and the Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, Ohio

Susan M. Begelman, MD
Section of Vascular Medicine, Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio

Amjad AlMahameed, MD
Section of Vascular Medicine, Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio

Correspondence: John R. Bartholomew, MD, Section of Vascular Medicine, S60, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; [email protected]

Dr. Bartholomew is a consultant for The Medicines Company and on the speakers' bureau of GlaxoSmithKline.

Dr. Begelman is a consultant for and on the speakers' bureau of GlaxoSmithKline.

Dr. AlMahameed has indicated that he has nothing to disclose.

John R. Bartholomew, MD
Section of Vascular Medicine, Department of Cardiovascular Medicine and the Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, Ohio

Susan M. Begelman, MD
Section of Vascular Medicine, Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio

Amjad AlMahameed, MD
Section of Vascular Medicine, Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio

Correspondence: John R. Bartholomew, MD, Section of Vascular Medicine, S60, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; [email protected]

Dr. Bartholomew is a consultant for The Medicines Company and on the speakers' bureau of GlaxoSmithKline.

Dr. Begelman is a consultant for and on the speakers' bureau of GlaxoSmithKline.

Dr. AlMahameed has indicated that he has nothing to disclose.

John R. Bartholomew, MD
Section of Vascular Medicine, Department of Cardiovascular Medicine and the Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, Ohio

Susan M. Begelman, MD
Section of Vascular Medicine, Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio

Amjad AlMahameed, MD
Section of Vascular Medicine, Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio

Correspondence: John R. Bartholomew, MD, Section of Vascular Medicine, S60, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; [email protected]

Dr. Bartholomew is a consultant for The Medicines Company and on the speakers' bureau of GlaxoSmithKline.

Dr. Begelman is a consultant for and on the speakers' bureau of GlaxoSmithKline.

Dr. AlMahameed has indicated that he has nothing to disclose.